Search Menu
Photonics Media Photonics Buyers' Guide Photonics Spectra BioPhotonics EuroPhotonics Vision Spectra Photonics Showcase Photonics ProdSpec Photonics Handbook
More News

Siemens Medical Solutions

Facebook Twitter LinkedIn Email Comments
The FDA has granted Siemens Medical Solutions of Hoffman Estates, Ill., an investigational new drug exemption to conduct a Phase I clinical trial on one of its molecular imaging biomarkers. The marker,18F 3'-fluoro-3'-deoxythymidine, could help monitor the proliferation of cancer cells in the context of cancer therapy assessment. Researchers from Memorial Sloan-Kettering Cancer Center in New York will carry out the study at their facility with colleagues from Siemens as part of a PET imaging biomarker research collaboration agreement.

Sep 2007
Biophotonicsmolecular imaging biomarkersNews & FeaturesSiemens Medical Solutions

back to top
Facebook Twitter Instagram LinkedIn YouTube RSS
©2019 Photonics Media, 100 West St., Pittsfield, MA, 01201 USA,

Photonics Media, Laurin Publishing
x Subscribe to BioPhotonics magazine - FREE!
We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.